Synthesis and cytotoxic activity of per-acetylated and halogenated derivatives of nucleosides in breast cancer cells
DOI:
https://doi.org/10.30827/ars.v58i4.6441Keywords:
anticancer nucleoside, breast cancer, cytotoxic activity, esterification and halogenation reactions, uridine and cytarabineAbstract
Objectives. To make the synthesis of halogenated derivatives on the nitrogenous base and their respective acyl ester and amide type derivatives for all hydroxyl and amine groups of the uridine and cytarabine nucleosides, and evaluate cytotoxicity against breast cancer cell line.
Methods. First, it was accomplished the halogenation reaction on the 5-position of the nitrogenous base, subsequently, the ester and amide derivatives were performed for all hydroxyl and amine group present in the nucleosides. Besides, the uridine acetonide derivatives as prepared by acid catalysis. The products were characterized by nuclear magnetic resonance spectroscopy (1H RMN y 13C RMN) and mass spectrometry in positive mode by direct injection. Derivatives were evaluated in Chinese hamster ovary (CHO-K1) and human breast cancer (MCF-7) cell lines.
Results. The four derivatives were obtained with chlorine and bromine for the uridine and cytarabine, respectively, their respective per-acetylated derivatives, the per-acetylated nucleoside and the uridine acetonide; the compounds were obtained with efficiency over 90%. The per-acetylated nucleosides and the halogenated and per-acetylated derivatives did not show inhibitory effects on cell viability in MCF-7 cell line. However, the per-acetylated and halogenated derivatives presented a higher cytotoxic activity than their respective per-acetylated nucleoside. The uridine 3’,4’-acetonide showed a significant cytotoxicity on both cell lines.
Conclusions. The per-acetylated nucleoside, and the respective halogenated derivatives with chlorine and bromine were obtained with high yields, nevertheless, these compounds did not exhibit a significant anti-proliferative activity (p˂0.05), possibly due to a low intra-cellular activation.
Downloads
References
Chik F, Machnes Z, Szyf M. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor s-adenosyl methionine and the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Carcinogenesis. 2014; 35(1):138–44.
Mehta DR, Foon K a, Redner RL, Raptis A, Agha M, Hou J-Z, et al. Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leuk Res. 2011; 35(7):885-8.
Moysan E, Bastiat G, Benoit J. Gemcitabine versus modified gemcitabine: a review of several promising chemical modification. Molecular pharmaceutics. 2013; 10:430-44.
Shelton J, Lu X, Hollenbaugh JA, Cho JH, Amblard F, Schinazi RF. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chem Rev. 2016; 116:14379-55.
Bzowska A, Kulikowska E, Shugar D. Purine nucleoside phophorylases: properties, functions and clinical aspects. Pharmacol Ther. 2000; 88(3):349–425.
Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009; 78(11):1351–9.
Sarpietro MG, Ottimo S, Giuffrida MC, Rocco F, Ceruti M, Castelli F. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int J Pharm. 2011; 406(1-2):69–77.
Chhikara BS, Mandal D, Parang K. Synthesis and evaluation of fatty acyl ester derivatives of cytarabine as anti-leukemia agents. Eur J Med Chem. 2010; 45(10):4601–8.
Radi M, Adema AD, Daft JR, Cho JH, Hoebe EK, Alexander LMM, et al. In Vitro Optimization of Non-Small Cell Lung Cancer Activity with Troxacitabine. J. Med. Chem. 2007; 50(7):2249–53.
Castelli F, Sarpietro MG, Rocco F, Ceruti M, Cattel L. Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique. J Colloid Interface Sci. 2007;313(1):363–8.
Yamamoto T, Koyama H, Kurajoh M, Shoji T, Tsutsumi Z, Moriwaki Y. Biochemistry of uridine in plasma. Clin Chim Acta. 2011; 412(19-20):1712–24.
Wandzik I, Bieg T, Czaplicka M. Synthesis of 2-deoxy-hexopyranosyl derivatives of uridine as donor substrate analogues for glycosyltransferases. Bioorg Chem. 2009; 37(6):211–6.
Murata S, Ichikawa S, Matsuda A. Synthesis of galactose-linked uridine derivatives with simple linkers as potential galactosyltransferase inhibitors. Tetrahedron. 2005; 61(24):5837–42.
Grosso Salis LF, Núñez Jaroque G, Berrío Escobar JF, Giordani C, Martínez Martínez A, Márquez Fernández DM, et al. Interaction of 3′,4′,6′-trimyristoyl-uridine derivative as potential anticancer drug with phospholipids of tumorigenic and non-tumorigenic cells. Appl Surf Sci. 2017; 426:77–86.
Szymanska-Michalak A, Wawrzyniak D, Framski G, Kujda M, Zgola P, Stawinski J, et al. New O-3’-aromatic acyl-5-fluoro-2’-deoxyuridine derivatives as potential anticancer agents. Eur J Med Chem. 2016; 115:41–52.
Berrío Escobar JF, Arango Carmona VH, Galeano Jaramillo E, Márquez Fernández DM, Márquez Fernández ME, Camargo Guerrero M, Martínez Martínez A. Synthesis and cytotoxic activity of tri-acyl ester derivatives of uridine in breast cancer cells. Ars Pharm. 2016; 57(2): 55-62.
Berrío Escobar JF, Pastrana Restrepo MH, Mejía Cuartas DM, Márquez Fer¬nández DM, Márquez Fernández ME, Martínez Martínez A. Synthesis and cytotoxic activity of conjugates of the uridine with triterpenes on breast cancer cells. Ars Pharm. 2016; 57(2):1-7.
Hrdlicka P.J, Jepsen J.S, Nielsen C, Wengela J. Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds C-3’-ethynyluridine (Eurd) And C-3’-ethynylcytidine (Ecyd). Bioorg. Med. Chem. 2005; 13:1249–60.
Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017; 123(2):345–56.
Santos C, Morgan BW, Geller RJ. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate. Am J Emerg Med. 2017; 35(5): 802.e7–802.e8.
Clayden J, Greeves N, Warren S. and Wothers P. Organic Chemistry. 2dn Ed. Oxford: Oxford University Press. 2012. 1234 p.
Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, et al. 5-fdurd–AraC heterodinucleoside re-establishes sensitivity in 5-fdurd- and AraC-resistant MCF-7 breast cancer cells overexpressing erbb2. Differentiation 2006; 74(9-10):488–98.
Morgan PE, Fine RL, Montgomery P, Marangos PJ. Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine. Cancer Chemother Pharmacol. 1991; 29:127–32.
Karle JM, Cowan KH, Chisena CA, Cysyk RL. Uracil Nucleotide Synthesis in a Human Breast Cancer Cell Line (MCF-7) and in Two Drug-Resistant Sublines that Contain Increased Levels of Enzymes of the de Novo Pyrimidine Pathway. Molecular Pharmacology. 1986; 30:136–41.
Downloads
Published
How to Cite
Issue
Section
License
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).